I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Jill Marie Broadfoot net worth and biography

Jill Broadfoot Biography and Net Worth

CFO of aTyr Pharma

Jill M. Broadfoot has served as our Chief Financial Officer since July 2018. From January 2017 to July 2018, Ms. Broadfoot served as Chief Financial Officer of Emerald Health Pharmaceuticals Inc. and Emerald Health Bioceuticals Inc., where she was responsible for establishing operations for the U.S.-based pharmaceutical and bioceutical entities as well as the establishment of operations, corporate governance, finance and accounting and investor relations functions, among others. Prior to Emerald Health, Ms. Broadfoot served as Vice President, U.S. Corporate Controller at GW Pharmaceuticals, from May 2016 to January 2017. While at GW Pharmaceuticals, her responsibilities included establishing U.S. commercial operations and implementing U.S. public company financial and accounting standards in connection with the transfer of corporate operations from the U.K. to the U.S. Prior to joining GW Pharmaceuticals, Ms. Broadfoot served as Chief Financial Officer of Vical Inc., from October 2004 to March 2013, where she had oversight of finance, investor relations, manufacturing, information technology, human resources, and business development. Prior to that, Ms. Broadfoot held various positions at DJO Global, Inc., most recently as Vice President of Finance, and served as an audit manager at Ernst & Young LLP. Ms. Broadfoot holds a B.S. in business administration and accounting from San Diego State University and is a Certified Public Accountant.

What is Jill Marie Broadfoot's net worth?: The estimated net worth of Jill Marie Broadfoot is at least $0.00 as of May 31st, 2024. Ms. Broadfoot owns 27,960 shares of aTyr Pharma stock worth more than $0 as of November 2nd. This net worth approximation does not reflect any other assets that Ms. Broadfoot may own. Additionally, Ms. Broadfoot receives an annual salary of $544,750.00 as CFO at aTyr Pharma. Learn More about Jill Marie Broadfoot's net worth.
How old is Jill Marie Broadfoot?: Ms. Broadfoot is currently 62 years old. There are 3 older executives and no younger executives at aTyr Pharma. The oldest executive at aTyr Pharma is Dr. David J. King Ph.D., Scientific Consultant, who is 65 years old. Learn More on Jill Marie Broadfoot's age.
What is Jill Marie Broadfoot's salary?: As the CFO of aTyr Pharma, Inc., Ms. Broadfoot earns $544,750.00 per year. The highest earning executive at aTyr Pharma is Dr. Sanjay S. Shukla M.D., M.S., President, CEO & Director, who commands a salary of $768,180.00 per year. Learn More on Jill Marie Broadfoot's salary.
How do I contact Jill Marie Broadfoot?: The corporate mailing address for Ms. Broadfoot and other aTyr Pharma executives is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. aTyr Pharma can also be reached via phone at (858) 731-8389 and via email at [email protected]. Learn More on Jill Marie Broadfoot's contact information.
Has Jill Marie Broadfoot been buying or selling shares of aTyr Pharma?: Jill Marie Broadfoot has not been actively trading shares of aTyr Pharma within the last three months. Most recently, on Friday, May 31st, Jill Marie Broadfoot bought 5,000 shares of aTyr Pharma stock. The stock was acquired at an average cost of $1.79 per share, with a total value of $8,950.00. Following the completion of the transaction, the chief financial officer now directly owns 27,960 shares of the company's stock, valued at $50,048.40. Learn More on Jill Marie Broadfoot's trading history.
Who are aTyr Pharma's active insiders?: aTyr Pharma's insider roster includes Jill Broadfoot (CFO), John Clarke (Director), Paul Schimmel (Director), and Sanjay Shukla (CEO). Learn More on aTyr Pharma's active insiders.
Are insiders buying or selling shares of aTyr Pharma?: In the last twelve months, aTyr Pharma insiders bought shares 4 times. They purchased a total of 78,000 shares worth more than $136,160.00. The most recent insider tranaction occured on May, 31st when CFO Jill Marie Broadfoot bought 5,000 shares worth more than $8,950.00. Insiders at aTyr Pharma own 3.7% of the company. Learn More about insider trades at aTyr Pharma.
Information on this page was last updated on 5/31/2024.

Jill Marie Broadfoot Insider Trading History at aTyr Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/31/2024	Buy	5,000	$1.79	$8,950.00	27,960
2/6/2023	Sell	1,566	$2.36	$3,695.76	15,460
1/13/2022	Buy	1,923	$6.75	$12,980.25
2/9/2021	Sell	390	$7.66	$2,987.40
6/19/2020	Buy	1,850	$4.22	$7,807.00	9,153
9/20/2018	Buy	64,000	$0.83	$53,120.00
9/14/2018	Buy	26,000	$0.73	$18,980.00

Jill Marie Broadfoot Buying and Selling Activity at aTyr Pharma

aTyr Pharma Company Overview

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Today's Range

Now: N/A

50 Day Range

MA: $1.76

$1.57

$2.07

2 Week Range

Now: N/A

Volume

269,400 shs

Average Volume

514,103 shs

Market Capitalization

$131.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

True paradigm shift

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

Jill Broadfoot Biography and Net Worth

What is Jill Marie Broadfoot's net worth?

How old is Jill Marie Broadfoot?

What is Jill Marie Broadfoot's salary?

How do I contact Jill Marie Broadfoot?

Has Jill Marie Broadfoot been buying or selling shares of aTyr Pharma?

Who are aTyr Pharma's active insiders?

Are insiders buying or selling shares of aTyr Pharma?